In medical technology, share prices do not always fall because the business breaks. Often, they decline because the market temporarily loses confidence in the pace of growth. When that happens, high-quality companies turn into patience trades, where the key question is not survival, but timing.
This case fits that pattern. Analysts see meaningful upside and expect a return to sustainable revenue growth above 10% annually, driven primarily by a fast-accelerating therapy segment. The divergence between overall company growth and the performance of this core engine is what matters most for investors, as it defines both the credibility of the recovery and the metrics that will shape sentiment over the coming quarters.
Top points of the analysis
The investment thesis is based on a return to 10%+ sustainable revenue growth to be underpinned by new product launches, indication expansion and market development, with TMT growing the fastest.
The company has superior profitability and a "cushion" on…